RESEARCH ARTICLE

Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary Syndrome

Cindy T. Pau¹, Tim Mosbruger², Richa Saxena³, Corrine K. Welt⁴*

¹ Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of America, ² Huntsman Cancer Institute Bioinformatics, University of Utah, Salt Lake City, Utah, United States of America, ³ Department of Anesthesiology and Center for Human Genetics, Massachusetts General Hospital, Boston, Massachusetts, United States of America, ⁴ Division of Endocrinology, Metabolism and Diabetes, University of Utah, Salt Lake City, Utah, United States of America

* cwelt@genetics.utah.edu

Abstract

Genome-wide association studies and replication analyses have identified (n = 5) or replicated (n = 10) DNA variants associated with risk for polycystic ovary syndrome (PCOS) in European women. However, the causal gene and underlying mechanism for PCOS risk at these loci have not been determined. We hypothesized that analysis of phenotype, gene expression and metformin response as a function of genotype would identify candidate genes and pathways that could provide insight into the underlying mechanism for risk at these loci. To test the hypothesis, subjects with PCOS (n = 427) diagnosed according to the NIH criteria (<9 menses per year and clinical or biochemical hyperandrogenism) and controls (n = 407) with extensive phenotyping were studied. A subset of subjects (n = 38) underwent a subcutaneous adipose tissue biopsy for RNA sequencing and were subsequently treated with metformin for 12 weeks with standardized outcomes measured. Data were analyzed according to genotype at PCOS risk loci and adjusted for the false discovery rate. A gene variant in the \textit{THADA} locus was associated with response to metformin and metformin was a predicted upstream regulator at the same locus. Genotype at the \textit{FSHB} locus was associated with LH levels. Genes near the PCOS risk loci demonstrated differences in expression as a function of genotype in adipose including \textit{BLK} and \textit{NEIL2} (GATA4 locus), \textit{GLIPR1} and \textit{PHLDA1} (KRR1 locus). Based on the phenotypes, expression quantitative trait loci (eQTL), and upstream regulatory and pathway analyses we hypothesize that there are PCOS subtypes. \textit{FSHB}, \textit{FHSR} and \textit{LHR} loci may influence PCOS risk based on their relationship to gonadotropin levels. The \textit{THADA}, \textit{GATA4}, \textit{ERBB4}, \textit{SUMO1P1}, \textit{KRR1} and \textit{RAB5B} loci appear to confer risk through metabolic mechanisms. The \textit{IRF1}, \textit{SUMO1P1} and \textit{KRR1} loci may confer PCOS risk in development. The \textit{TOX3} and \textit{GATA4} loci appear to be involved in inflammation and its consequences. The data suggest potential PCOS subtypes and point to the need for additional studies to replicate these findings and identify personalized diagnosis and treatment options for PCOS.
Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive age women, affecting 7–10% of this group. Cardinal features include irregular menstrual cycles, hyperandrogenism and polycystic ovarian morphology [1]. Obesity and insulin resistance are also common, along with increased risk of diabetes, metabolic syndrome and other cardiovascular diseases [2, 3]. Despite the detrimental impact of the disorder on women’s health, the etiology remains poorly understood.

Twin studies suggest that genetic influences explain over 70% of PCOS pathogenesis [4]. Therefore, genome-wide association studies have been performed to uncover DNA variants associated with PCOS [5–9]. There are now 16 published variants that mark loci associated with PCOS in women of Han Chinese and European ethnicity. It is not clear which variants in the loci are causal for increased risk of PCOS nor which genes in the loci are marked by the genotyped variants. Insights have been gained previously through association with quantitative phenotype traits and PCOS subphenotypes [7, 9, 10]. Insight has also been gained through examination of gene expression in tissues of interest in other diseases, including type 2 diabetes [11–14].

We therefore hypothesized that the relationship between PCOS risk loci and quantitative phenotypic traits would illuminate the underlying PCOS features affected at each locus. We also hypothesized that gene expression and associated patterns would identify candidate genes and pathways that could provide insight into the risk mechanism at the loci. The data suggest relationships between PCOS risk variants and gonadotropins, reproductive, metabolic and developmental pathways.

Results

Phenotype/Genotype Analysis

LH levels (genotype GG 18.8 ± 0.7, GA 24.0 ± 1.8, AA 27.7 ± 3.1 IU/L; p = 1.13x10^-5) and the LH: FSH ratio (GG 1.8 ± 0.05, GA 2.4 ± 0.1, AA 2.5 ± 0.3; p = 1.1X10^-9) were associated with genotype at rs11031006, near the FSHβ gene (Fig 1). Other phenotypic traits were not associated with genotype except as previously reported [15].

Gene Expression

The number of reads was 30.3X10^6 ± 4.9 X10^6, uniquely aligned reads was 23.5X10^6 ± 4.5 X10^6 (77 ± 8%), and the number of exonic reads was 9.6X10^6 ± 3.5 X10^6 (40 ± 11% of the unique reads). Skin and fat RNA expression clusters did not overlap and were therefore analyzed separately. Four samples did not cluster with their respective tissue types and were removed from the analysis (3 fat and 1 skin).

In adipose, BLK demonstrated increased expression (3.8 ± 1.2-fold, p_adj = 0.0005) and NEIL2 nominally decreased expression (-0.8 ± 0.3-fold, p_adj = 0.057) at the rs804279 (GATA4/NEIL2) locus. GLIPR1 (2.7 ± 0.7-fold, p_adj = 1.2X10^-5) and PHLDA1 (3.1 ± 0.5-fold, p_adj = 4.2X10^-12) demonstrated increased expression at the rs1795379 (KRR1) locus. There was nominally decreased expression of DENND1A (-0.6 ± 0.3-fold, p_nom = 0.02) at the rs10986105 (DENND1A) locus. There were no significant relationships when expression of genes within the same loci were examined in skin.

Metformin Response

Subjects who carried the rs12478601-C PCOS risk variant were more likely to respond to metformin with lower basal glucose (χ^2 = 9.1, p = 0.002; CC -4.15 ± 2.22, CT -3.33 ± 5.8, TT 2.03
Fig 1. LH and the LH:FSH ratio as a function of genotype at rs11031006 in PCOS and control subjects. *p<0.05.
doi:10.1371/journal.pone.0168870.g001
±7.24 mg/dL; p<0.003). There were no additional significant relationships between genotype and metformin response parameters. Metformin was predicted as an upstream regulator for THADA rs12478601 variant carriers (p = 3X10^-6; S1 Table).

Upstream Regulators

The top 5 predicted upstream regulators for each variant are shown in Table 1. The entire list of upstream regulators is shown in S1 Table.

The most common upstream regulators included TGFB1 (THADA, FSHR, LHCGR, DENND1A, KRR1, TOX3) and the immune and inflammatory regulators tumor necrosis factor, interleukins and interferon gamma (THADA, FSHR, LHCGR, GATA4/NEIL2, DENND1A, ERBB3, KRR1, TOX3). Other upstream regulators included mitochondrial genes and AMPK upstream at the ERBB4 locus, important for energy production. Transcription factors HOXA9, TP53 and GATA2 were upstream regulators of SUMO1P1 and KRR1, respectively. ERBB2 was an upstream regulator of THADA and KRR1.

Canonical Pathways

The expression patterns at the majority of the loci overlapped with several canonical pathways involved in the immune and inflammatory response (Table 2 and S2 Table). In addition, the expression pattern at rs12478601 in fat (THADA locus) overlapped with a canonical pathway involved in adipogenesis. In skin, canonical pathways included cholesterol biosynthesis pathways.

The expression pattern for rs2178575 (ERBB4 locus) in skin overlapped with canonical pathways involved in mitochondrial dysfunction, oxidative phosphorylation and MAPK signaling. The expression pattern for r2268361 (FSHR locus), rs13405728 (LHCGR locus) and rs1795379 (KRR1 locus) overlapped with a canonical pathway involved in axonal guidance. The expression pattern at two loci overlapped with canonical pathways involved in ErbB signaling (rs13164856; IRF1 locus) and ErbB2 signaling (rs11031005; FSHB locus).

Associated Networks

The expression pattern at rs12478601 (THADA locus) in skin and fat, rs804279 (GATA4 locus) and rs1795379 (KRR1 locus) in fat and rs2268361 (FSHR locus) in skin predicted involvement in reproductive diseases (Table 3). The expression pattern at rs11031005 (FSHβ locus) in fat predicted a relationship to endocrine function and the pattern for rs2178575 (ERBB4 locus) in skin predicted a relationship to metabolic disease.

All of the loci were associated with at least one network involved in cell processes, including cell-to-cell signaling, movement, cell function and maintenance, cell growth, proliferation and development and cell death and survival. In addition, 8 loci were associated with networks predicted to involve embryonic development (THADA, ERBB4, FSHR, RAD50, DENND1A, FSHβ, KRR1, SUMO1P1). Finally, 7 loci were associated with cholesterol or lipid biosynthesis (THADA, FSHR, LHCGR, RAD50, FSHβ, RAB5B, SUMO1P1).

Discussion

The risk attributed to genetic loci associated with PCOS can be understood only through fine mapping to locate the causal risk allele and identification of the candidate genes affected. Phenotype, both baseline and interrogated, and expression data from adipose and skin of women with PCOS suggest candidate genes and pathways that predispose to PCOS at the genetic risk loci. Specifically, phenotype data from current and previous studies suggest risk in relation to
Table 1. Top five upstream regulators predicted by pattern of gene expression as a function of genotype at polycystic ovary syndrome risk loci. Three variants, rs4385527 (C9orf3), rs2272046 (HMG2A) and rs2059807 (INSR), did not have data available.

| Variant   | Chr | Nearest Gene | Tissue | TGFB1 | ERBB2/ERBB3 | PDGFBB | VEGF | IGFI | EGF | EREG | FSH | Estradiol | Mifepristone | Dexamethasone | Drospirenone | Genistein | Tretinoin | Phorbol Esters |
|-----------|-----|--------------|--------|--------|-------------|---------|------|------|-----|------|-----|-----------|---------------|---------------|--------------|-----------|-----------|---------------|
| rs12478601 | 2   | THADA        | Fat    | X      | X           |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs12478601 | 2   | THADA        | Skin   |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs2178575  | 2   | E6B4         | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs2178575  | 2   | E6B4         | Skin   |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs2268361  | 2   | FSHR         | Fat    |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |
| rs2268361  | 2   | FSHR         | Skin   |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |
| rs13405728 | 2   | LHGGR        | Skin   |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |
| rs13164856 | 5   | RAD50        | Skin   |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |
| rs804279   | 8   | GATA4/NEIL2  | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs10986105 | 9   | DENND1A      | Fat    |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |
| rs2479106  | 9   | DENND1A      | Skin   |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs11031006 | 11  | FSHB         | Skin   |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs11031005 | 11  | FSHB         | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs705702   | 12  | RAB5B/SUOX   | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs705702   | 12  | RAB5B/SUOX   | Skin   |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs2271194  | 12  | E6B3         | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs1795379  | 12  | KIR1         | Fat    |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |
| rs4784165  | 16  | TOX3         | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs6022786  | 20  | SUMO1P1      | Fat    |        |             |         |      |      |     |      |     |           |               |               |             |           |           |               |
| rs6022786  | 20  | SUMO1P1      | Skin   |        |             | X       |      |      |     |      |     |           |               |               |             |           |           |               |

Continued...
| rs1795379 | 12 | KRR1  | Fat | X | X | X | X |
| rs4784165  | 16 | TOX3  | Fat | X | X | X | X |
| rs6022786  | 20 | SUMO1P1 | Fat | X | X | X | X |
| rs6022786  | 20 | SUMO1P1 | Skin | X | X | X | X |

doi:10.1371/journal.pone.0168870.t001
Table 2. Top five canonical pathways identified by gene expression patterns at each polycystic ovary syndrome genetic risk locus.

| Variant     | Candidate Gene(s) | Tissue | Ingenuity Canonical Pathways |
|-------------|-------------------|--------|-----------------------------|
| rs1795379   | KRR1              | Fat    | Actin Cytoskeleton Signaling |
| rs2479106   | DENND1A           | Skin   | Acyl-CoA Hydrolysis          |
| rs12478601  | THADA             | Fat    | Adipogenesis pathway        |
| rs4784165   | TOX3              | Fat    | Agranulocyte Adhesion and Diapedesis |
| rs2178575   | ERBB4             | Fat    | Allograft Rejection Signaling |
| rs2479106   | DENND1A           | Skin   | Antigen Presentation Pathway |
| rs2268361   | FSHR              | Fat    | Aryl Hydrocarbon Receptor Signaling |
| rs10986105  | DENND1A           | Fat    |                          |
| rs11031006  | FSHB              | Skin   | Atherosclerosis Signaling   |
| rs2178575   | ERBB4             | Fat    |                          |
| rs2178575   | TOX3              | Fat    | Autoimmune Thyroid Disease Signaling |
| rs2268361   | FSHR              | Skin   | Axonal Guidance Signaling  |
| rs13405728  | LHCGR             | Skin   |                          |
| rs1795379   | KRR1              | Fat    |                          |
| rs2479106   | DENND1A           | Skin   | B Cell Development        |
| rs705702    | RAB5B/SUOX        | Fat    | B Cell Receptor Signaling  |
| rs11031005  | FSHB              | Fat    |                          |
| rs10986105  | DENND1A           | Fat    | Basal Cell Carcinoma Signaling |
| rs705702    | RAB5B/SUOX        | Fat    | CD28 Signaling in T Helper Cells |
| rs804279    | GATA4/NEIL2       | Fat    |                          |
| rs13164856  | RAD50             | Skin   | Ceramide Degradation       |
| rs12478601  | THADA             | Skin   | Cholesterol Biosynthesis I |
| rs12478601  | THADA             | Skin   | Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) |
| rs12478601  | THADA             | Skin   | Cholesterol Biosynthesis III (via Desmosterol) |
| rs11031005  | FSHB              | Fat    | Complement System          |
| rs2268361   | FSHR              | Skin   | Ephrin Receptor Signaling  |
| rs13405728  | LHCGR             | Skin   |                          |
| rs1795379   | KRR1              | Fat    |                          |
| rs13164856  | RAD50             | Skin   | Epoxysqualene Biosynthesis |
| rs13164856  | RAD50             | Skin   | ErbB Signaling            |
| rs12478601  | THADA             | Fat    | Ethanol Degradation II     |
| rs2479106   | DENND1A           | Skin   | Eumelanin Biosynthesis     |
| rs705702    | RAB5B/SUOX        | Skin   | Fatty Acid Activation      |
| rs705702    | RAB5B/SUOX        | Skin   | Fatty Acid β-oxidation I   |
| rs6022786   | SUMO1P1           | Skin   | FXR/RXR Activation         |
| rs2271194   | ERBB3             | Fat    | Glucocorticoid Receptor Signaling |
| rs13405728  | LHCGR             | Fat    |                          |
| rs4784165   | TOX3              | Fat    | Granulocyte Adhesion and Diapedesis |
| rs2178575   | ERBB4             | Fat    | Hematopoiesis from Pluripotent Stem Cells |
| rs10986105  | DENND1A           | Fat    | Hepatic Fibrosis / Hepatic Stellate Cell Activation |
| rs1795379   | KRR1              | Fat    |                          |
| rs4784165   | TOX3              | Fat    |                          |
| rs11031005  | FSHB              | Fat    | HER-2 Signaling in Breast Cancer |
| rs2268361   | FSHR              | Fat    | HGF Signaling             |
| rs13405728  | LHCGR             | Fat    | HMGB1 Signaling           |
| rs4784165   | TOX3              | Fat    |                          |
| rs705702    | RAB5B/SUOX        | Fat    | iCOS-iCOSL Signaling in T Helper Cells |
| rs804279    | GATA4/NEIL2       | Fat    |                          |

(Continued)
| Variant   | Candidate Gene(s) | Tissue | Ingenuity Canonical Pathways                                                                 |
|-----------|-------------------|--------|----------------------------------------------------------------------------------------------|
| rs13405728 | LHCGR             | Fat    | IL-17A Signaling in Fibroblasts                                                                |
| rs11031005 | FSHB              | Fat    | IL-3 Signaling                                                                              |
| rs13405728 | LHCGR             | Fat    | IL-6 Signaling                                                                              |
| rs2268361  | FSHR              | Fat    | JAK/Stat Signaling                                                                           |
| rs6022786  | SUMO1P1          | Skin   | Leucine Degradation I                                                                         |
| rs804279   | GATA4/NEIL2       | Fat    | Leukocyte Extravasation Signaling                                                             |
| rs2268361  | FSHR              | Skin   |                                                                                              |
| rs10986105 | DENND1A           | Fat    | LPS/IL-1 Mediated Inhibition of RXR Function                                                   |
| rs6022786  | SUMO1P1          | Skin   |                                                                                              |
| rs6022786  | SUMO1P1          | Fat    | LXR/RXR Activation                                                                            |
| rs2178575  | ERBB4             | Skin   | Mitochondrial Dysfunction                                                                     |
| rs13405728 | LHCGR             | Skin   | Molecular Mechanisms of Cancer                                                                 |
| rs13164856 | RAD50             | Skin   | NADH Repair                                                                                  |
| rs705702   | RAB5B/SUOX       | Fat    | Natural Killer Cell Signaling                                                                 |
| rs804279   | GATA4/NEIL2       | Fat    |                                                                                              |
| rs12478601 | THADA             | Fat    | Noradrenaline and Adrenaline Degradation                                                        |
| rs2178575  | ERBB4             | Skin   | Oxidative Phosphorylation                                                                     |
| rs2178575  | ERBB4             | Skin   | p38 MAPK Signaling                                                                            |
| rs2178575  | ERBB4             | Fat    | Primary Immunodeficiency Signaling                                                              |
| rs2268361  | FSHR              | Fat    | Proline Biosynthesis II (from Arginine)                                                        |
| rs2271194  | ERBB3             | Fat    |                                                                                              |
| rs10986105 | DENND1A           | Fat    | Prostanoid Biosynthesis                                                                       |
| rs2268361  | FSHR              | Fat    | Protein Citrullination                                                                        |
| rs2271194  | ERBB3             | Fat    |                                                                                              |
| rs2178575  | ERBB4             | Skin   |                                                                                              |
| rs6022786  | SUMO1P1           | Fat    | Pyridoxal 5’-phosphate Salvage Pathway                                                          |
| rs1795379  | KRR1              | Fat    | Rac Signaling                                                                                 |
| rs11031006 | FSHB              | Skin   | Retinoate Biosynthesis I                                                                      |
| rs12478601 | THADA             | Fat    |                                                                                              |
| rs2271194  | ERBB3             | Fat    | Role of IL-17A in Psoriasis                                                                    |
| rs2268361  | FSHR              | Skin   | Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis                   |
| rs13405728 | LHCGR             | Fat    |                                                                                              |
| rs13405728 | LHCGR             | Skin   |                                                                                              |
| rs2268361  | FSHR              | Skin   | Role of Tissue Factor in Cancer                                                                |
| rs6022786  | SUMO1P1           | Fat    | Salvage Pathways of Pyrimidine Ribonucleotides                                                   |
| rs2271194  | ERBB3             | Fat    | Serine Biosynthesis                                                                           |
| rs12478601 | THADA             | Fat    | Sertoli Cell-Sertoli Cell Junction Signaling                                                   |
| rs6022786  | SUMO1P1           | Fat    | Spermine and Spermidine Degradation I                                                           |
| rs13164856 | RAD50             | Skin   | Sphingosine and Sphingosine-1-phosphate Metabolism                                               |
| rs705702   | RAB5B/SUOX       | Skin   | Stearate Biosynthesis I (Animals)                                                               |
| rs2479106  | DENND1A           | Skin   |                                                                                              |
| rs6022786  | SUMO1P1           | Skin   |                                                                                              |
| rs705702   | RAB5B/SUOX       | Skin   | Superpathway of Cholesterol Biosynthesis                                                        |
| rs12478601 | THADA             | Skin   |                                                                                              |
| rs12478601 | THADA             | Skin   | Superpathway of Geranylgeranylphosphate Biosynthesis I (via Mevalonate)                          |
| rs705702   | RAB5B/SUOX       | Fat    | T Cell Receptor Signaling                                                                      |
| rs804279   | GATA4/NEIL2       | Fat    |                                                                                              |
| rs13405728 | LHCGR             | Skin   | Thrombin Signaling                                                                             |

(Continued)
gonadotropins and glucose metabolism. Interrogation with metformin points to a locus with type 2 diabetes risk. The expression data point to the importance of growth factors and inflammatory and immune pathways in upstream regulation and effector pathways including reproductive, endocrine, metabolism and inflammatory pathways. The differences in potential upstream regulators and networks affected in the case of each variant point to potentially differing etiologies for PCOS risk at the distinct risk loci.

The phenotype insights are most helpful to ascertain. The rs11031006 variant is associated with LH levels and the LH:FSH ratio, as we previously reported for the rs12294104, which is in linkage disequilibrium [7, 16]. The variant is located upstream of FSHβ and larger studies demonstrate that FSH levels are also suppressed in the presence of the variant [7, 17]. Therefore, the variant may act as an upstream suppression site lowering FSH levels, with the resulting free α subunit pairing with LHβ and increasing LH levels [18, 19]. FSHβ expression was not evaluable in adipose or skin and the effect of the variant could not be examined in these tissues. The expression pattern in relation to the variant did predict involvement in endocrine development and disease. Finally, the overlap between the expression pattern at the FSHβ locus and ERBB2 signaling is supported by the relationship between gonadotropins, estradiol and HER-2 upregulation in breast cancer patients [20].

The rs12478601-C variant, identified initially in women of Han Chinese ethnicity and replicated in European women, was found in the only PCOS risk locus that predicted any defined response to metformin [6, 21, 22]. An independent THADA locus has been extensively evaluated and is associated with a lower insulin sensitivity in one study and decreased beta cell responsiveness [23]. Further, the expression pattern overlaps with the canonical adipogenesis pathway. Taken together, the data point to a relationship between the THADA locus in PCOS and the independent causal association with insulin resistance and metabolism [7].

There were few variants associated with gene expression at the loci identified. In carriers of the rs804279-A risk allele (GATA4 locus), B cell non-receptor Src tyrosine kinase expression (BLK) was increased, a gene responsible for B-cell receptor signaling and B-cell development. It is a susceptibility gene for multiple autoimmune phenotypes. Interestingly, BLK protein also stimulates insulin synthesis and secretion in response to glucose and enhances expression of β cell transcription factors [24]. One hypothesis would be that the increased expression is a response to insulin resistance in PCOS. NEIL2 was nominally decreased at the same locus, a gene that plays a role in gene maintenance and protection from DNA mutagenesis and the inflammatory response [25]. Upstream regulators at the locus were also dominated by inflammatory and immune genes. Taken together, the increase in expression of an autoimmune risk gene and trend toward decreased expression of an inflammatory suppression gene may point to an inflammatory risk profile in PCOS.

---

**Table 2. (Continued)**

| Variant   | Candidate Gene(s) | Tissue | Ingenuity Canonical Pathways                           |
|-----------|-------------------|--------|--------------------------------------------------------|
| rs11031006| FSHB              | Skin   | Thymine Degradation                                   |
| rs11031006| FSHB              | Skin   | Trehalose Degradation II (Trehalase)                   |
| rs6022786 | SUMO1P1           | Skin   | Triacylglycerol Biosynthesis                          |
| rs11031006| FSHB              | Skin   | Uracil Degradation II (Reductive)                     |
| rs11031005| FSHB              | Fat    | Virus Entry via Endocytic Pathways                    |
| rs6022786 | SUMO1P1           | Fat    | Zymosterol Biosynthesis                               |
| rs705702  | RAB5B/SUOX        | Skin   | γ-linolenate Biosynthesis II (Animals)                 |

**Table 2 (Continued)**

| Variant | Candidate Gene(s) | Tissue | Ingenuity Canonical Pathways |
|---------|-------------------|--------|-----------------------------|
| rs12294104 | FSHB      | Skin   | Thymine Degradation          |
| rs11031004 | FSHB      | Skin   | Trehalose Degradation II (Trehalase) |
| rs6022786 | SUMO1P1   | Skin   | Triacylglycerol Biosynthesis |
| rs11031006 | FSHB      | Skin   | Uracil Degradation II (Reductive) |
| rs11031005 | FSHB      | Fat    | Virus Entry via Endocytic Pathways |
| rs6022786 | SUMO1P1   | Fat    | Zymosterol Biosynthesis      |
| rs705702  | RAB5B/SUOX | Skin   | γ-linolenate Biosynthesis II (Animals) |

*doi:10.1371/journal.pone.0168870.t002*
| Variant  | Chr | Nearest Gene | Tissue | Reproductive Disease | Endocrine Function | Dermatologic Disease | Lipid Biosynthesis or Metabolism | Embryonic Development | Cell Growth & Proliferation | Cell-Cell Signaling | Cell Function and Maintenance |
|----------|-----|--------------|--------|----------------------|-------------------|----------------------|---------------------------------|-----------------------|-----------------------------|------------------|------------------------------|
| rs12478601 | 2   | THADA        | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
| rs2178575  | 2   | ErbB4        | Fat    |                      |                    |                     |                                |                       |                             |                   |                              |
| rs2268361  | 2   | FSHR         | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
| rs13405728 | 2   | LHCGR        | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
| rs13164856 | 5   | RAD50        | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
| rs804279   | 8   | GATA4/NEIL2  | Fat    |                      |                    |                     |                                |                       |                             |                   |                              |
| rs2479106  | 9   | DENND1A      | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
| rs11031005 | 11  | FSHB         | Fat    |                      |                    |                     |                                |                       |                             |                   |                              |
| rs705702   | 12  | RAB5B/SUOX   | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
| rs1795379  | 12  | KRR1         | Fat    |                      |                    |                     |                                |                       |                             |                   |                              |
| rs6022786  | 20  | SUMO1P1      | Skin   |                      |                    |                     |                                |                       |                             |                   |                              |
At rs1795379 (KRR1 locus), there was increased expression of GLIPR1 and PHLDA1. PHLDA1 is the pleckstrin homology like domain family A member 1, a proline-histidine rich nuclear protein that plays an important role in the anti-apoptotic effects of insulin-like growth factor-1 (IGF-1) [26]. Interestingly, PHLDA1 is induced by IGF-1 and insulin upregulates IGF-1 receptors in conditions with insulin resistance, as in PCOS [27]. GLIPR1, or GLI pathogenesis related 1, has proapoptotic activity in prostate cancer cells, is expressed at high levels in the testes and may have a role in sperm-oocyte interactions [28]. The increased gene expression points to possible relationships to insulin resistance and fertility at the locus, as suggested by the overlap in expression as a function of the rs1795379 and pathways involved in reproduction.

A variant located in an intron of DENND1A demonstrated a nominal decrease in DENND1A expression although it was no longer significant after correction for multiple testing [10, 21]. Although rs2479106 was not initially replicated, it was the variant replicated in the recent metaanalysis GWAS of data from European women [8], but was not associated with expression and not in linkage disequilibrium with rs10986105. Upstream regulators of rs10986105 include several factors important in reproductive pathways. For example, JUN is induced by GnRH and TGFβ1 is important for reproductive regulation and has been implicated in PCOS [29, 30].

Previous studies have demonstrated differential gene expression in adipose tissue at the RAB5B and INSR PCOS risk loci [31]. The gene expression patterns at these two loci did not replicate in the current study. The loci with significant expression data were found in new loci that were not assessed in the previous study [31].

The IPA upstream regulatory analytic identified upstream transcriptional regulators that can explain observed gene expression differences as a function of genotype at each locus. The IPA network analysis integrates upstream regulators with downstream effects that may explain what is happening upstream and how it influences a phenotype or functional outcome downstream. The most common upstream regulators belong to the immunomodulatory and inflammatory axis. Previous studies have examined the association between polycystic ovary syndrome risk and variants in 80 inflammatory genes and found no association [32]. However, the study did not examine pathways that may influence PCOS through PCOS risk loci identified by GWAS, as in the current study. The second most common upstream regulators included growth factors, notably TGFβ1. TGFβ1 is important for reproductive regulation and has been implicated in PCOS [29, 30]. The networks affected are mainly related to cell growth, maintenance and embryonic development. These upstream regulators and networks may be specific to adipose and skin tissue sources. Adipose tissue and skin have previously been demonstrated to share the most cis-effects in the regulatory regions [12]. Study of additional tissues may provide differing expression patterns and further insight into the mechanism of risk at these PCOS loci.

The analysis pathways also suggest the hypothesis that these loci confer risk for PCOS through distinct mechanisms. The FSHB, FSHR and LHCGR loci influence PCOS risk based on their relationship to gonadotropin levels, as demonstrated in the current study and previous studies [7, 9, 15]. The THADA, GATA4, ERBB4, SUMO1P1 and KRR1 loci appear to confer risk through metabolic mechanisms. The RAB5B locus also appears to confer risk through metabolic mechanisms, particularly through glucose metabolism, as described previously [15]. KRR1 and DENND1A expression patterns suggest reproductive function. The IRF1, SUMO1P1 and KRR1 loci may confer PCOS risk through a developmental mechanism. The TOX3 and GATA4 loci appear to be involved in inflammation and its consequences.

The main limitation is the small sample size for PCOS-specific adipose and skin tissue expression. These studies will need replication in additional, larger PCOS cohorts. Other limitations include the possibility that the tissues examined in the current study are not those that...
are critical for functional expression of all genes. We also used subcutaneous adipose, which may not reflect important expression differences in visceral adipose, although it has been demonstrated to be similar for a small number of relevant genes [33, 34] associated previously with metabolic risk in PCOS. The subcutaneous adipocytes are also larger in women with PCOS and had lower lipoprotein lipase activity, suggesting a qualitative abnormality [35]. Ideally, ovarian tissue and pituitary/hypothalamic tissue should be studied next. By examining only cis-eQTLs we are potentially missing trans-eQTL effects [12]. However, given the small sample size there is concern for overcalling relationships. Finally, we did not examine controls because the hypothesis addressed possible eQTL effects in women with PCOS.

Phenotype data demonstrate a strong relationship between the risk alleles and gonadotropin levels. The data also demonstrate candidate genes at two PCOS risk loci marked by GATA4/NEIL2 and KRR1. Expression patterns as a function of genotype point to specific influences on PCOS risk at each locus spanning reproductive, metabolic and inflammatory pathways and response to metformin maps to a locus that has a metabolic profile. These data suggest the hypothesis that PCOS can be subdivided into differing risk patterns that may be able to pinpoint the underlying etiology as a function of genotype.

Methods

Study Subjects

Subjects were of European ethnicity, aged 18–45 years old and with PCOS defined by the NIH criteria, i.e. irregular menses (< 9 menstrual periods/yr) and clinical or biochemical hyperandrogenism (n = 427)[36]. Clinical hyperandrogenism was defined as a Ferriman Gallwey (FG) score greater than 9, the upper 95% confidence limit for the Boston-based control populations. Biochemical hyperandrogenism was defined as an androgen level greater than the 95 percent confidence limits in control subjects with regular, ovulatory menstrual cycles: testosterone >63 ng/mL (2.8 nmol/L), DHEAS >430 μg/dL (1.16 μmol/L) or androstenedione levels >3.8 ng/mL (0.13 nmol/L). Subjects with non-classic congenital adrenal hyperplasia, hypothyroidism, elevated prolactin levels, diabetes, Cushing syndrome and primary ovarian insufficiency were excluded [37]. Control subjects (n = 407) consisted of women aged 18–45 years with regular menses, between 21 and 35 days, and no hyperandrogenism [37]. Subjects were on no hormonal medication for at least 3 months and no medications that influence insulin, inflammation, or lipid levels for at least one month. A subset of subjects, meeting all criteria for PCOS as described above, were also studied in a protocol in which metformin was administered (n = 38)[36].

Protocol

All PCOS subjects were studied ≥10 days after their last menstrual period and after a 12 hour fast [37]. Subjects underwent a detailed history; physical exam including measurement of waist circumference at the umbilicus and hip circumference at the widest diameter; a pelvic ultrasound (Phillips, 5 MHz convex array transducer); and blood samples for DNA, lipids, glucose, insulin, gonadotropin and sex-steroid levels. LH and FSH levels were obtained at ten minute intervals to calculate an average gonadotropin concentration. Using data from blood samples collected every 10 min over 12 h in women with PCOS and ovulatory controls [38], we documented that the mean LH secretion from 12 h of frequent blood samples correlates well with the value obtained from the mean of three samples collected from 0800–0820 h (r = 0.92, p<0.01) [37].

The subset of 38 subjects with PCOS also underwent an intravenous glucose tolerance test (IVGTT), with glucose 0.3 g/kg administered at time 0 and regular human insulin 0.03 U/kg.
injected at 20 minutes [22]. They subsequently underwent a subcutaneous adipose biopsy 
under local anesthesia with 1% lidocaine. Adipose tissue and skin, which was saved for 16 sub-
jects, were rinsed with sterile 0.9% NaCl solution, placed on ice and transported for immediate 
freezing in liquid nitrogen.

After the initial visit, subjects started treatment with metformin ER 500 mg per day, with 
the dose increasing by 500 mg every two weeks to a final dose of 1500 mg/day, which was 
administered for a total of 12 weeks. Subjects returned every two weeks for anthropomorphic 
measurements, estradiol and progesterone levels, and a pelvic ultrasound to monitor folliculo-
genesis. Subjects returned for additional visits if follicle size indicated impending ovulation. 
Compliance was determined by questioning at the biweekly visits. After 12 weeks of metfor-
min ER 1500 mg/day, subjects were admitted to the Massachusetts General Hospital Clinical 
Research Center to repeat the study as outlined above. Plasma metformin levels were measured 
in the fasting state at the study conclusion before the final IV glucose tolerance test. Clinical 
parameters were previously reported [22].

The study was approved by the Partners Human Research Committee. All subjects pro-
vided written, informed consent.

Genotyping, RNA Sequencing and Statistical Analysis

Patient DNA was isolated from whole blood according to manufacturer’s specifications (Qia-
gen, USA) and genotyped using the HumanOmniExpress BeadChip (Illumina, San Diego). 
Associations between five SNPs not previously examined in our data (Table 1 and S3 Table) 
and PCOS phenotypes were evaluated [7–9].

Linear regression using an additive genetic model was used to test for association of PCOS 
risk variants with 30 log-transformed quantitative traits in the combined sample of PCOS 
cases and controls in the discovery Boston cohort. A \( p \) value < 0.0003 was considered signifi-
cant after Bonferroni correction for 12 evaluable gene variants (S3 Table) and 15 independent 
traits (FSH, LH, prolactin, 17-OH progesterone, testosterone, cholesterol, sex hormone bind-
ing globulin (SHBG), estradiol, blood pressure, pulse, thyroid stimulating hormone (TSH), 
body mass index (BMI), fasting glucose, fasting insulin and ovarian volume), with other vari-
ables highly correlated.

Associations between genetic variants and response to metformin were analyzed using Chi 
square [39] and one way ANOVA. To correct for multiple testing, a \( p \) value of 0.0021 was con-
sidered significant to correct for comparisons of 2 independent outcomes (change in baseline 
glucose and glucose mediated glucose disposal, and testosterone and ovulation) and 12 evalu-
able variants.

SNPs from all loci associated with PCOS in European and Chinese GWAS and available on 
the HumanOmniExpress BeadChip were examined in relation to adipose and skin expression 
[5–9].

Skin (n = 10) and adipose tissue (n = 33) were isolated, tissue homogenized and RNA 
extracted (RNeasy or RNeasy lipid kits, Qiagen, USA). RNA libraries were prepared using Illu-
mina TruSeq strand RNA sample prep with RiboZero treatment and sequencing was per-
formed using the Illumina HiSeq 50 cycle single-read sequencing.

Transcript annotations for hg19 (build 74) were downloaded from Ensembl. Splice junction 
sequences were generated using the USeq (v8.8.2) MakeTranscriptome application using a 
radius of 46. Novoindex (2.8) was used to create a transcriptome index using the combined 
splice junction and hg19 chromosome sequences.

Reads were aligned to the transcriptome index described above using Novoalign (v2.08.01), 
allowing up to 50 alignments for each read. USeq (v8.8.2) SamTranscriptomeParser was used
to convert the coordinates of reads aligning to splice junctions to genomic space. Reads aligning to multiple locations in the genome with equal confidence were discarded.

Ensembl Build 74 transcript annotations were collapsed into gene annotations using USeq (v8.8.2) MergeUCSCGeneTable. USeq (v8.8.8) DefinedRegionDifferentialSeq was used to generate read counts for each gene. DESeq2 was used to test for differential expression in any of the genotypes using the likelihood ratio test (LRT) option [40]. Genes with significant adjusted p-values were used in Ingenuity Pathway Analysis (IPA®, Ingenuity Systems, QIAGEN) and for eQTL expression analysis. For eQTL expression analysis, all genes within an LD block defined by an $r^2 = 0.1$ were considered. In addition, expression in fat and skin for all genes within 1 MB of the variant of interest were examined, which encompassed the LD block defined above. Pathway analysis was performed using IPA®, which creates algorithmically generated pathways from expression data and compares the ratio of overlap to known pathways. The upstream regulator data is generated by determining differentially expressed genes between genotypes and comparing them to genes regulated by the upstream molecules to determine the significance of enrichment of the gene expression data for the genes downstream of an upstream regulator. For both pathway and upstream regulator analysis, significance is calculated using the Fisher exact test.

Supporting Information

S1 Table. Upstream regulators identified in adipose and skin at gene loci associated with risk for polycystic ovary syndrome.

(XLSX)

S2 Table. Top five canonical pathways identified by gene expression patterns at each polycystic ovary syndrome genetic risk locus.

(XLSX)

S3 Table. Gene variants associated with polycystic ovary syndrome risk.

(DOCX)

Author Contributions

Conceptualization: CTP CKW.

Data curation: RS.

Formal analysis: TM RS CKW CTP.

Funding acquisition: CKW.

Investigation: CW CTP.

Methodology: TM RS CKW.

Project administration: CTP.

Software: TM RS.

Supervision: CKW.

Visualization: CTP CKW.

Writing – original draft: CTP CKW.

Writing – review & editing: CTP TM RS CKW.
References

1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41–47 PMID: 14688154

2. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endo Rev 1995; 16:322–353

3. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141–146 PMID: 10339316

4. Vink JM, Sadrzadeh S, Lambek CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006; 91:2100–2104 doi: 10.1210/jc.2005-1494 PMID: 16219714

5. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, Zhang B, Li T, Chen J, Zhao J, You L, Gao X, Zhu D, Zhao X, Yan Y, Qin Y, Li W, Yan J, Wang Q, Zhao J, Geng L, Ma J, Zhao Y, He G, Zhang A, Zou S, Yang A, Liu J, Li W, Li B, Wan C, Qin Y, Shi J, Yang J, Jiang H, Xu JE, Qi X, Sun Y, Zhang Y, Hao G, Ju X, Zhao D, Ren CE, Li X, Zhang W, Zhang Y, Zhang J, Wu D, Zhang C, He L, Chen ZJ. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 2012; 44:1020–1025 doi: 10.1038/ng.2384 PMID: 22885925

6. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J, Liang X, Zhao X, Zhao J, Sun Y, Zhang B, Jiang H, Zhao D, Bian Y, Gao X, Geng L, Li Y, Zhu D, Sun X, Xu JE, Hao C, Ren CE, Zhang Y, Chen S, Zhang W, Yang A, Yan J, Li M, Zhao J. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43:55–59 doi: 10.1038/ng.732 PMID: 21151128

7. Day FR, Hands DA, Tung JY, Stolk L, Styrrkardottir U, Saxena R, Bjorness A, Broer L, Dunger DB, Hall-dorsson BV, Lawlor DA, Laval G, Mathieson I, McCarrdile WL, Louwers Y, Meun C, Ring S, Scott RA, Sulem P, Uitterlinden AG, Wareham NJ, Thorsteinsdottir U, Welt C, Stefansson K, Laven JS, Ong KK, Perry JR. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun 2015; 6:8464 doi: 10.1038/ncomms9464 PMID: 26167640

8. Meun CK, T.;Magi,R.;Drong,A.W.;Armstron g,L.;Broer,L.;Jones,M.R.;Day ,F.R.;PCOS Genetics Con-sortium. Program #933: Genome-wide meta-analysis of polycystic ovary syndrome in women of Euro-pean ancestry identifies new loci in hormone pathways. Presented at the 65th Annual meeting of the American Society of Human Genetics October 7, 2015, Baltimore, MD

9. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, Karaderi T, Barber TM, McCarthy MI, Frankis S, Lindgren CM, Welt CK, Diamanti-Kandarakis E, Panidias D, Goodarzi MO, Azziz R, Zhang Y, James RG, Olivier M, Kissebah AH, Reproductive Medicine N, Steren-Victorin E, Legro RS, Dunaf A. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6:7502 doi: 10.1038/ncomms8502 PMID: 26284813

10. Welt CK, Styrrkardottir U, Ehrmann DA, Thorleifsson G, Arason G, Gudmundsson JA, Ober C, Rosenfield RL, Saxena R, Thorsteinsdottir U, Crowley WF, Stefansson K. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab 2012; 97:E1342–1347 doi: 10.1210/jc.2011-3478 PMID: 22547425

11. van de Bunt M, Manning Fox JE, Dai X, Barrett A, Grey C, Li L, Bennett AJ, Johnson PR, Rajotte RV, Gaulton K, Dermitzakis ET, MacDonald PE, McCarthy MJ, Gioyn AL. Transcript Expression Data from Human Islets Links Regulatory Signals from Genome-Wide Association Studies for Type 2 Diabetes and Glycemic Traits to Their Downstream Effectors. PLoS Genet 2015; 11:e1005694 doi: 10.1371/ journal.pgen.1005694

12. Grundberg E, Small KS, Hedman AK, Nica AC, Bui A, Keildson S, Bell JT, Yang TP, Meduri E, Barrett A, Nisbett J, Sekowska M, Wilk A, Shin SY, Glass D, Travers M, Min JL, Ring S, Ho K, Thorleifsson G, Kong A, Thorsteinsdottir U, Ainali C, Dimas AS, Hassanali N, Ingle C, Knowles D, Krestyaninova M, Lowe CE, Di Meglio P, Montgomery SB, Parts L, Potter S, Surduslescu G, Tsaprouni L, Tsoka S, Batile V, Durbin R, Nestle FO, O’Rahilly S, Soranzo N, Lindgren CM, Zondervan KT, Ahmad KR, Schadt EE, Stefansson K, Smith GD, McCarthy MI, Deloukas P, Dermitzakis ET, Spector TD, Multiple Tissue Human Expression Resource C. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012; 44:1084–1089 doi: 10.1038/ng.2394 PMID: 22941192

13. Small KS, Hedman AK, Grundberg E, Nica AC, Thorleifsson G, Kong A, Thorsteinsdottir U, Shin SY, Richards HB, Consortium G, Investigators M, Consortium D, Soranzo N, Ahmadi KR, Lindgren CM, Stefansson K, Dermitzakis ET, Deloukas P, Spector TD, McCarthy MI, Mu TC. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet 2011; 43:561–564 doi: 10.1038/ng.833 PMID: 21572415
14. Fairfax BP, Humburg P, Makino S, Narainbhai V, Wong D, Lau E, Jostins L, Plant K, Andrews R, McGee C, Knight JC. Innate immune activity conditions the effect of regulatory variants upon monoocyte gene expression. Science 2014; 343:1246949 doi: 10.1126/science.1246949 PMID: 24604202

15. Saxena R, Bjornes AC, Georgopoulos NA, Koika V, Panidis D, Welt CK. Gene variants associated with age at menopause are also associated with polycystic ovary syndrome, gonadotropins and ovarian volume. Hum Reprod 2015; 30:1697–1703. doi: 10.1093/humrep/det110 PMID: 25994816

16. Saxena R, Bjornes AC, Georgopoulos NA, Koika V, Panidis D, Welt CK. Gene variants associated with age at menopause are also associated with polycystic ovary syndrome, gonadotropins and ovarian volume. Human reproduction. 2015; 30(7):1697–703. doi: 10.1093/humrep/det110 PMID: 25994816

17. Ruth KS, Campbell PJ, Chew S, Lim EM, Hadlow N, Stucky BG, Brown SJ, Feenstra B, Joseph J, Surdulescu GL, Zheng HF, Richards JB, Murray A, Spector TD, Wilson SG, Perry JR. Genome-wide association study with 1000 genomes imputation identifies signals for nine sex hormone-related phenotypes. Eur J Hum Genet 2015;

18. Abel MH, Widen A, Wang X, Huhtaniemi I, Pakarinen P, Kumar TR, Christian HC. Pituitary Gonadotrophic Hormone Synthesis, Secretion, Subunit Gene Expression and Cell Structure in Normal and Follicle-Stimulating Hormone beta Knockout, Follicle-Stimulating Hormone Receptor Knockout, Luteinising Hormone Receptor Knockout, Hypogonadal and Ovariectomised Female Mice. J Neuroendocrinol 2014; 26:785–795 doi: 10.1111/jne.12178 PMID: 25039914

19. Fortin J, Boehm U, Deng CX, Treier M, Bernard DJ. Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2. FASEB J 2014; 28:3396–3410 doi: 10.1096/fj.14-249352 PMID: 24739304

20. Luftner D, Jung A, Schmid P, Wemecke KD, Possinger K, Takeda Adjuvant Breast Cancer Study with Leuprorelin Study G. Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients. Breast Cancer Res Treat 2003; 80:245–255 PMID: 14503797

21. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD, Krauss RM, Rotter JI, Ankene r W, Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity:

22. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD, Krauss RM, Rotter JI, Ankene r W, Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity:

23. Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF-beta in polycystic ovary syndrome.

24. Simonis- Bik AM, Nijpels G, van Haeften TW, Houwing-Duistermaat JJ, Boomsma DI, Reiling E, van

25. Thackray VG, Mellon PL, Coss D. Hormones in synergy: regulation of the pituitary gonadotropin genes.

26. Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF-beta in polycystic ovary syndrome.

27. Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF-beta in polycystic ovary syndrome.

28. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endo Rev 1999; 20:535–582

29. Gibbs GM, Lo JC, Nixon B, Jamsai D, O’Connor AE, Rijal S, Sanchez-Partida LG, Heam MT, Bianco DM, O’Bryan MK. Glioma pathogenesis-related 1-like 1 is tests enriched, dynamically modified, and redistributed during male germ cell maturation and has a potential role in sperm-oocyte binding. Endocrinology 2010; 151:2331–2342 doi: 10.1210/en.2009-1255 PMID: 20219979

30. Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF-beta in polycystic ovary syndrome. Reprod Sciences 2014; 21:20–31

Phenotype and Gene Expression in PCOS
31. Jones MR, Brower MA, Xu N, Cui J, Mengesha E, Chen YD, Taylor KD, Azziz R, Goodarzi MO. Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity. PLoS Genet 2015; 11:e1005455 doi: 10.1371/journal.pgen.1005455 PMID: 26305227

32. Bhatt S, Mutharasaran P, Garcia OA, Jafari N, Legro RS, Dunai A, Urbanek M. The inflammatory gene pathway is not a major contributor to polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99: E567–571 doi: 10.1210/jc.2013-2342 PMID: 24423322

33. Carmina E, Chu MC, Moran C, Tortorello D, Vardhana P, Tena G, Preciado R, Lobo R. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril 2008; 89:642–648 doi: 10.1016/j.fertnstert.2007.03.085 PMID: 17562334

34. Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013; 98:E388–396 doi: 10.1210/jc.2012-3414 PMID: 23337724

35. Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. The Journal of clinical endocrinology and metabolism. 2011; 96:E304–11 doi: 10.1210/jc.2010-1290 PMID: 21084397

36. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Guðlaugsdóttir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. The Journal of clinical endocrinology and metabolism. 2006; 91:4842–8 doi: 10.1210/jc.2006-1327 PMID: 17003085

37. Welt CK, Arason G, Gudmundsson JA, Adams J, Palsdottir H, Guðlaugsdóttir G, et al. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. The Journal of clinical endocrinology and metabolism. 2006; 91:4361–8 doi: 10.1210/jc.2006-1111 PMID: 16940441

38. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 1997; 82:2248–56 doi: 10.1210/jcem.82.7.4105 PMID: 9215302

39. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21:263–5 doi: 10.1093/bioinformatics/bth457 PMID: 15297300

40. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15:550 doi: 10.1186/s13059-014-0550-8 PMID: 25516281